Patent search ipc:C07D213/81 Page 1

1.

发明授权
Theramutein modultors 有权

公开(公告)号：US12226420B2

公开(公告)日：2025-02-18

申请号：US18433881

申请日：2024-02-06

Applicant: HMI MEDICAL INNOVATIONS, LLC

Inventor： Gerard M. Housey

IPC: A61K31/5377 , A61K31/166 , A61K31/175 , A61K31/195 , A61K31/27 , A61K31/415 , A61K31/4196 , A61K31/44 , A61K31/4436 , A61K31/444 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/505 , A61K31/506 , A61K31/517 , A61K31/53 , C07C243/38 , C07D213/77 , C07D213/81 , C07D213/86 , C07D213/87 , C07D215/38 , C07D215/50 , C07D231/14 , C07D239/42 , C07D239/48 , C07D239/84 , C07D253/065 , C07D253/075 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , G01N33/50 , G01N33/573 , G01N33/574

Abstract: This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.

2.

发明授权
Ethynyl derivatives 有权

公开(公告)号：US12195413B2

公开(公告)日：2025-01-14

申请号：US17338643

申请日：2021-06-03

Applicant: Hoffmann-La Roche Inc.

Inventor： Georg Jaeschke , Lothar Lindemann , Antonio Ricci , Eric Vieira

IPC: C07C11/22 , A61K31/4166 , A61K31/4184 , A61K31/44 , A61K31/4439 , A61P1/00 , A61P1/04 , A61P25/00 , A61P25/04 , A61P25/16 , A61P25/18 , A61P25/22 , A61P25/24 , A61P25/28 , A61P29/00 , A61P43/00 , C07D213/81 , C07D401/04 , C07D403/04

Abstract: The present invention relates to ethynyl derivatives of formula I with variables as defined herein, or to a pharmaceutically acceptable acid addition salt thereof Compounds of formula I are metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).

3.

发明授权
Water-soluble ynamide coupling reagent and preparation method and use thereof 有权

公开(公告)号：US12180175B2

公开(公告)日：2024-12-31

申请号：US17475486

申请日：2021-09-15

Applicant: Xi'an Easy Peptide Biotechnology Co., Ltd.

Inventor： Junfeng Zhao , Tao Liu

IPC: C07D317/28 , C07C67/03 , C07C67/08 , C07C201/12 , C07C231/02 , C07C269/06 , C07C327/22 , C07C327/26 , C07C329/04 , C07D213/81 , C07D213/83 , C07D215/48 , C07D295/185 , C07D333/70 , C07J1/00 , C07K5/06

Abstract: The present disclosure discloses a water-soluble ynamide coupling reagent and a method for using the water-soluble ynamide coupling reagent in the synthesis of amide, polypeptide, ester and thioester compound. The ynamide coupling reagent has the structure represented by the following formula (I): and in the formula (I), R is one selected from the group consisting of methylsulfonyl, benzenesulfonyl, p-toluenesulfonyl, trifluoroacetyl and other electron withdrawing groups.

4.

发明授权
Picolinamides as fungicides 有权

公开(公告)号：US12180163B2

公开(公告)日：2024-12-31

申请号：US17483232

申请日：2021-09-23

Applicant: CORTEVA AGRISCIENCE LLC

Inventor： Brian A. Loy , Nicolaas Vermeulen , Brannon Sam , Kevin G. Meyer , Chenglin Yao , Nicholas R. Babij , Jeff Petkus

IPC: C07D213/81 , A01N37/02 , A01N43/10 , A01N43/40 , A01N43/84 , A01N47/18 , C07B53/00 , C07C229/28 , C07C271/18 , C07D213/83 , C07D333/08 , C07D409/12 , C07D498/04

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

5.

发明申请
PSMA Imaging Agents 有权

公开(公告)号：US20240409580A1

公开(公告)日：2024-12-12

申请号：US18809625

申请日：2024-08-20

Applicant: Siemens Medical Solutions USA, Inc.

Inventor： Eric Wang , Hartmuth C. Kolb , Anna Katrin Szardenings , Changhui Liu , Joseph C. Walsh , Gang Chen , Anjana Sinha , Dhanalakshmi Kasi , Chul Yu , Umesh B. Gangadharmath , Wei Zhang , Tieming Zhao , Vani P. Mocharla

IPC: C07K5/02 , A61K38/00 , A61K51/04 , A61K51/08 , C07D207/16 , C07D209/48 , C07D213/81 , C07D213/82 , C07D233/78 , C07D233/96 , C07D239/60 , C07D249/04 , C07D249/06 , C07D251/30 , C07D263/34 , C07D277/56 , C07D401/12 , C07D403/06 , C07D403/12 , C07D405/12 , C07K5/062 , C07K5/072

Abstract: Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

6.

发明公开
SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE 审中-公开

公开(公告)号：US20240336568A1

公开(公告)日：2024-10-10

申请号：US18742052

申请日：2024-06-13

Applicant: Akebia Therapeutics, Inc.

Inventor： Thomas P. BLAISDELL , Paul E. FLEMING

IPC: C07D213/81 , A61K31/4418 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/502 , A61K31/5377 , C07D213/84 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D417/04 , C07D471/04 , C07D495/04

CPC classification number: C07D213/81 , A61K31/4418 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/498 , A61K31/502 , A61K31/5377 , C07D213/84 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D417/04 , C07D471/04 , C07D495/04

Abstract: The present invention provides, in part, compounds and methods for treating diseases mediated by PHD1 activity (e.g., ischemia reperfusion injury (including but not limited to stroke, myocardial infarction, and acute kidney injury) inflammatory bowel disease, cancer (including colorectal cancer) and liver disease) comprising administering to a subject to a subject a compound of Formula (I), and sub-formulas thereof:

or a pharmaceutically acceptable salt thereof.

7.

发明公开
Compositions and Methods for Treating Anemia 审中-公开

公开(公告)号：US20240325361A1

公开(公告)日：2024-10-03

申请号：US18500471

申请日：2023-11-02

Applicant: Akebia Therapeutics, Inc.

Inventor： Alexander Smith , Gurudatt Ajay Chandorkar , Ene Ikpong Ette , Bradley John Maroni , Charlotte Suzanne Hartman , Ramin Farzaneh-Far , Jula Kern Inrig

IPC: A61K31/4418 , A61K9/20 , A61K9/28 , A61K31/16 , C07D213/81

CPC classification number: A61K31/4418 , A61K9/2009 , A61K9/2013 , A61K9/2054 , A61K9/2059 , A61K9/2866 , A61K31/16 , C07D213/81

Abstract: Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia secondary to or associated with non-dialysis dependent chronic kidney disease anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

8.

发明公开
A NEW MOLECULAR SCAFFOLD FOR TARGETING HRPN13 审中-公开

公开(公告)号：US20240317732A1

公开(公告)日：2024-09-26

申请号：US18262941

申请日：2022-01-28

Applicant: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE

Inventor： Kylie J. Walters , Xiuxiu LU , Nadya I. Tarasova , Eric Rolf SWENSON , Venkatareddy SABBASANI , Beverly Ann MOCK , Snehal GAIKWAD , Deborah CITRIN , Monika CHANDRAVANSHI

IPC: C07D417/14 , C07C255/44 , C07C311/46 , C07D213/81 , C07D401/14 , C07D403/12 , C07D417/12

CPC classification number: C07D417/14 , C07C255/44 , C07C311/46 , C07D213/81 , C07D401/14 , C07D403/12 , C07D417/12

Abstract: In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to scaffold molecules having anti-hRPN13 activity, proteolysis targeting chimeras (PROTACs) incorporating the same, methods of making same, pharmaceutical compositions comprising same, and methods of treating cancers involving aberrant hRpn13 activity and/or the presence of hRpn13-Pru/hRpn13 or variants thereof using the same.